CRISPR Therapeutics

224 articles with CRISPR Therapeutics

• CRISPR Therapeutics Announces Departure of Board Member

  3/29/2023

  CRISPR Therapeutics today announced that Brad Bolzon, Ph.D., Chairman and Managing Director of Versant Ventures, is stepping down from the Board of Directors after nearly a decade of service.

• Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes

  3/27/2023

  Vertex Pharmaceuticals Incorporated today announced that they have entered into a new non-exclusive licensing agreement for the use of CRISPR Therapeutics’ gene editing technology, known as CRISPR/Cas9, to accelerate the development of Vertex’s hypoimmune cell therapies for type 1 diabetes (T1D).

• CRISPR Therapeutics to Present at the American Association for Cancer Research 2023 Annual Meeting

  3/14/2023

  CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced an oral presentation of preclinical data at the American Association for Cancer Research (AACR) 2023 Annual Meeting, taking place April 14 – 19, 2023, in Orlando, FL.

• 

  CRISPR/ViaCyte and Genprex Vie for First Diabetes Gene Therapy

  3/13/2023

  Partners CRISPR and ViaCyte (Vertex), and Genprex are pioneers in the quest to develop a gene therapy for Type 1 diabetes.

• CRISPR Therapeutics Announces Transition of Chief Financial Officer - March 13, 2023

  3/13/2023

  CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announces the hiring and appointment of Raju Prasad, Ph.D., as Chief Financial Officer, effective March 14, 2023.

• CRISPR Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference

  2/27/2023

  CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in a fireside chat at 43rd Annual Cowen Health Care Conference on Monday, March 6, 2023, at 10:30 a.m. ET.

• CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

  2/21/2023

  CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2022.

• CRISPR Therapeutics to Participate in Upcoming Investor Conferences - February 8, 2023

  2/8/2023

  CRISPR Therapeutics today announced that members of its senior management team are scheduled to participate in fireside chats at the following investor conferences in February.

• CRISPR Therapeutics to Participate in B. Riley Securities’ 3rd Annual Oncology Conference

  1/11/2023

  CRISPR Therapeutics today announced that members of its senior management team are scheduled to participate in B. Riley Securities’ 3rd Annual Oncology Conference on Wednesday, January 18, 2023, at 10:30 a.m. ET.

• 

  2022's Top Clinical Advancements: See Pivotal Data in NASH, Alzheimer’s, Sickle Cell Disease

  12/23/2022

  2022 featured pivotal data that could change the landscape in non-alcoholic steatohepatitis, Alzheimer’s disease, sickle cell disease and many more indications.
• 

  bluebird's SCD Gene Therapy Released from Partial Hold

  12/20/2022

  The FDA lifted its partial clinical hold on bluebird's experimental sickle cell disease gene therapy for patients younger than 18.

• CRISPR Therapeutics Announces the Appointment of Alex Harding, M.D., M.B.A., as Head of Business Development

  12/19/2022

  CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Alex Harding, M.D., M.B.A., as Senior Vice President and Head of Business Development, effective January 5, 2023.

• CRISPR Therapeutics Provides Update on Its Ongoing Phase 1 CARBON™ Trial of CTX110®

  12/12/2022

  CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today provided an update for both Part A and Part B of the Company’s ongoing Phase 1 CARBON trial evaluating the safety and efficacy of CTX110®, its wholly-owned allogeneic CAR T cell therapy targeting CD19+ B-cell malignancies.

• Vertex and CRISPR Therapeutics to Present at the American Society of Hematology (ASH) Annual Meeting and Exposition

  12/10/2022

  Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics announced an oral, encore presentation of clinical data from patients with sickle cell disease or transfusion-dependent beta-thalassemia treated with the investigational therapy exagamglogene autotemcel in CLIMB-111 or CLIMB-121 and followed in CLIMB-131, a long-term follow-up study.

• CRISPR Therapeutics to Present at the 2022 BMO Growth & ESG Conference

  12/1/2022

  CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in a fireside chat at the 2022 BMO Growth & ESG Conference on Wednesday, December 7, 2022, at 1:00 p.m. ET.

• 

  Novel Gene Therapy Approaches for Solid Tumors on Display at SITC

  11/11/2022

  PACT Pharma shared results of a first-of-its-kind trial using CRISPR technology to swap a gene in a patient’s immune cell to treat solid tumors.

• CRISPR Therapeutics Presents Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

  11/10/2022

  CRISPR Therapeutics today presented data for CTX130™ for the treatment of relapsed or refractory renal cell carcinoma (RCC) as an oral presentation delivered by City of Hope’s Sumanta Pal, M.D.

• CRISPR Therapeutics Announces Poster Presentation on CTX110® at the American Society of Hematology (ASH) 2022 Annual Meeting

  11/3/2022

  CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that it will present a poster on CTX110®, its wholly-owned allogeneic CAR-T cell investigational therapy targeting CD19+ B-cell malignancies, at the American Society of Hematology (ASH) 2022 Annual Meeting, taking place December 10-13, 2022.

• CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results

  11/1/2022

  CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the third quarter ended September 30, 2022.

• CRISPR Therapeutics Announces Planned Transition of Chief Operating Officer

  10/27/2022

  CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that its Chief Operating Officer, Lawrence Klein, Ph.D., will be stepping down from the Company to pursue external opportunities.